Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.43 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188822 | 1.00 | ROCK2 (0.47) | ROCK2PIK3CAROCK1GAADGAT2 | |
| SCHEMBL27188878 | 0.88 | PIK3CA (0.47) | ROCK2PIK3CAROCK1GAASOST | |
| SCHEMBL29896106 | 0.88 | PIK3CA (0.47) | ROCK2PIK3CAROCK1GAASOST | |
| SCHEMBL29896123 | 0.88 | ROCK2 (0.50) | ROCK2ROCK1GAA | |
| SCHEMBL27188838 | 0.88 | ROCK2 (0.50) | ROCK2ROCK1GAA | |
| SCHEMBL27188865 | 0.87 | PIK3CA (0.44) | ROCK2PIK3CAGAASOSTTLR2 | |
| SCHEMBL29896162 | 0.87 | PIK3CA (0.44) | ROCK2PIK3CAGAASOSTTLR2 | |
| SCHEMBL29896169 | 0.86 | PIK3CA (0.45) | ROCK2PIK3CAROCK1DGAT2SOST | |
| SCHEMBL29896151 | 0.86 | L3MBTL1 (0.53) | ROCK2PIK3CAROCK1 | |
| SCHEMBL27188804 | 0.86 | PIK3CA (0.45) | ROCK2PIK3CAROCK1DGAT2SOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | ROCK2 4595/4885PIK3CA 3041/4885ROCK1 4416/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | ROCK2 4595/4885PIK3CA 3041/4885ROCK1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.